NEW YORK (GenomeWeb News) – Genetic Technologies announced today it has reached an agreement with AutoImmun Diagnostika to settle a dispute over the German firm's use of GTG's non-coding DNA technology.
As a result, GTG has granted non-exclusive rights to AutoImmun covering several of its patents. Further details of the licensing agreement were not disclosed.
AutoImmun was not a counterparty to two patent infringement suits initiated by GTG and ongoing in the US, the Australian firm said.